Late-life restoration of mitochondrial function reverses cardiac dysfunction in old mice.
Ying Ann ChiaoHuiliang ZhangMariya SweetwyneJeremy WhitsonYing Sonia TingNathan BasistyLindsay K PinoEllen QuarlesNgoc-Han NguyenMatthew D CampbellTong ZhangMatthew J GaffreyGennifer MerrihewLu WangYongping YueDongsheng DuanHenk L GranzierHazel H SzetoWei-Jun QianDavid MarcinekMichael J MacCossPeter S RabinovitchPublished in: eLife (2020)
Diastolic dysfunction is a prominent feature of cardiac aging in both mice and humans. We show here that 8-week treatment of old mice with the mitochondrial targeted peptide SS-31 (elamipretide) can substantially reverse this deficit. SS-31 normalized the increase in proton leak and reduced mitochondrial ROS in cardiomyocytes from old mice, accompanied by reduced protein oxidation and a shift towards a more reduced protein thiol redox state in old hearts. Improved diastolic function was concordant with increased phosphorylation of cMyBP-C Ser282 but was independent of titin isoform shift. Late-life viral expression of mitochondrial-targeted catalase (mCAT) produced similar functional benefits in old mice and SS-31 did not improve cardiac function of old mCAT mice, implicating normalizing mitochondrial oxidative stress as an overlapping mechanism. These results demonstrate that pre-existing cardiac aging phenotypes can be reversed by targeting mitochondrial dysfunction and implicate mitochondrial energetics and redox signaling as therapeutic targets for cardiac aging.